Last reviewed · How we verify
placebo (for macitentan)
A placebo is an inert substance with no active pharmacological mechanism.
A placebo is an inert substance with no active pharmacological mechanism. Used for Control comparator in macitentan clinical trials.
At a glance
| Generic name | placebo (for macitentan) |
|---|---|
| Sponsor | University of California, Los Angeles |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebos are used as control comparators in clinical trials to measure the efficacy of an active drug by comparison. In this case, it serves as the control arm in trials evaluating macitentan, an endothelin receptor antagonist. Any observed effects are attributable to the placebo effect or natural disease progression rather than direct molecular action.
Approved indications
- Control comparator in macitentan clinical trials
Common side effects
Key clinical trials
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension (PHASE3)
- Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (PHASE3)
- A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension (PHASE3)
- A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease (PHASE2)
- Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients (PHASE3)
- Macitentan to Prevent PRVO (PHASE3)
- A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH) (PHASE3)
- Macitentan in the Treatment of Organ Rejection After Lung Transplantation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo (for macitentan) CI brief — competitive landscape report
- placebo (for macitentan) updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI